EQIX vs ESPR · P/E 79, rev $9.22B vs rev $332.3M
Equinix Inc (EQIX) versus Esperion Therapeutics Inc (ESPR) — a side-by-side from cached financials, not a winner call.
Equinix Inc (EQIX) is a reit - specialty company listed on US.
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported EQIX revenue for 2025-12-31 was $9.22B. Net income was $1.35B. Revenue was up 5.4% from 2024-12-31 to 2025-12-31. EQIX currently screens at market cap $74.23B and trailing P/E 79.4.
Latest reported ESPR revenue for 2024-12-31 was $332.3M. Net income was -$51.7M. Revenue was up 185.7% from 2023-12-31 to 2024-12-31. ESPR currently screens at market cap $816.9M.
EQIX currently screens at market cap $74.23B and trailing P/E 79.4. ESPR currently screens at market cap $816.9M.
Not investment advice. Open the EQIX and ESPR stock pages for the full models.
Not investment advice.